BRIEF-Akari Therapeutics Announces Shareholder Approval In Connection With Peak Bio Merger-March 2024-www.financetom.com

BRIEF-Akari Therapeutics Announces Shareholder Approval In Connection With Peak Bio Merger

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Akari Therapeutics Announces Shareholder Approval In Connection With Peak Bio Merger

Nov 9, 2024 1:06 PM

Nov 8 (Reuters) - Akari Therapeutics PLC ( AKTX ):

* AKARI THERAPEUTICS ANNOUNCES SHAREHOLDER APPROVAL IN

CONNECTION

WITH PEAK BIO, INC. MERGER

* AKARI THERAPEUTICS PLC ( AKTX ) - MERGER TO RESULT IN 50% EQUITY

OWNERSHIP FOR AKARI AND PEAK BIO SHAREHOLDERS

Source text:

Further company coverage:

([email protected])

Previous page： TotalEnergies CEO says LNG prices will soften by end of decade Next page： Ferguson Stock Drops As Q2 EPS Miss, Margin Squeeze Overshadow Sales Growth

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

TotalEnergies CEO says LNG prices will soften by end of decade

Mar 11, 2025

HOUSTON (Reuters) - TotalEnergies CEO Patrick Pouyanné said on Tuesday at the CERAWeek energy conference in Houston that he expected liquefied natural gas prices to soften by the end of the decade. ...

Ferguson Stock Drops As Q2 EPS Miss, Margin Squeeze Overshadow Sales Growth

Mar 11, 2025

Ferguson Enterprises Inc. ( FERG ) shares are trading lower after the company reported second-quarter results. The company reported net sales of $6.87 billion, which was 3.0% higher year over year, beating the consensus of $6.76 billion. Net sales growth was driven by organic revenue growth of 2.1% and acquisition growth of 1.2%. Total volume increased by approximately 5%, with organic volume up 4%. Meanwhile, weakness in certain commodity-related categories...

Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal

Mar 11, 2025

On Monday, Bristol Myers Squibb & Co ( BMY ) agreed to acquire 2seventy bio, Inc. ( TSVT ) at $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal, which represents an 88% premium to the closing price of $2.66 on March 7, 2025, is expected...

Enphase Energy Starts Shipping IQ EV Charger 2 Across 14 European Markets

Mar 11, 2025

10:16 AM EDT, 03/11/2025 (MT Newswires) -- Enphase Energy ( ENPH ) said Tuesday it has started shipping its IQ EV Charger 2 across 14 European countries. The new charger works with the company's solar and battery systems and also operates as a standalone charger, Enphase said. The IQ EV charger is now available in Norway, Germany, the UK, France,...